Australia markets closed
  • ALL ORDS

    7,624.30
    +23.80 (+0.31%)
     
  • ASX 200

    7,368.90
    +9.90 (+0.13%)
     
  • AUD/USD

    0.7487
    -0.0064 (-0.85%)
     
  • OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD

    1,763.90
    -10.90 (-0.61%)
     
  • BTC-AUD

    47,533.16
    -205.43 (-0.43%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • AUD/EUR

    0.6308
    -0.0028 (-0.44%)
     
  • AUD/NZD

    1.0787
    +0.0009 (+0.09%)
     
  • NZX 50

    12,551.93
    +10.73 (+0.09%)
     
  • NASDAQ

    14,049.58
    -114.22 (-0.81%)
     
  • FTSE

    7,017.47
    -135.96 (-1.90%)
     
  • Dow Jones

    33,290.08
    -533.37 (-1.58%)
     
  • DAX

    15,448.04
    -279.63 (-1.78%)
     
  • Hang Seng

    28,801.27
    +242.68 (+0.85%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     

Global Non-Hodgkin Lymphoma Markets, Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com

·2-min read

The "Global Non-Hodgkin Lymphoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Global Non-Hodgkin Lymphoma Epidemiology and Patient Flow Analysis - 2021, provides Non-Hodgkin Lymphoma epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.

The research provides population data to characterize Non-Hodgkin Lymphoma patients, history of the disease at the population level (Non-Hodgkin Lymphoma prevalence, Non-Hodgkin Lymphoma incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.

Research scope:

  • Non-Hodgkin Lymphoma patient flow: Non-Hodgkin Lymphoma prevalence, diagnosed, and drug-treated patients

  • Countries: US, Germany, France, Italy, Spain, UK, Japan, G7 Countries

  • Demographics: Non-Hodgkin Lymphoma patients by age group, gender

  • Forecast: Non-Hodgkin Lymphoma epidemiology forecast to 2035

The data from this research will help executives:

  • Establish basis for Non-Hodgkin Lymphoma market sizing, assessing market potential, and developing drug forecast models

  • Identify Non-Hodgkin Lymphoma patients segments through age groups, gender, and disease sub-types

  • Develop Non-Hodgkin Lymphoma population-based health management frameworks

  • Evaluate Non-Hodgkin Lymphoma market opportunities, identify target patient population

  • Align marketing decisions with the Non-Hodgkin Lymphoma target population

  • Communicate leadership and health authorities about your Non-Hodgkin Lymphoma target patient population

Key Topics Covered:

1. Research Methodology

2. Non-Hodgkin Lymphoma Patients Definition

3. US Non-Hodgkin Lymphoma Epidemiology and Patient Flow

4. Germany Non-Hodgkin Lymphoma Epidemiology and Patient Flow

5. France Non-Hodgkin Lymphoma Epidemiology and Patient Flow

6. Italy Non-Hodgkin Lymphoma Epidemiology and Patient Flow

7. Spain Non-Hodgkin Lymphoma Epidemiology and Patient Flow

8. UK Non-Hodgkin Lymphoma Epidemiology and Patient Flow

9. Europe Non-Hodgkin Lymphoma Epidemiology and Patient Flow

10. Japan Non-Hodgkin Lymphoma Epidemiology and Patient Flow

11. Global Non-Hodgkin Lymphoma Epidemiology and Patient Flow

For more information about this report visit https://www.researchandmarkets.com/r/bo6cow

View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005845/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting